
7 Steps to Prescribing Lecanemab for Alzheimer’s
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.

Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.

Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide

There are no approved treatments for DLB, though it is the second most common type of dementia. Do drugs like donepezil hold the key?

While the initial headlines might seem discouraging, there’s always more to the story. 🌟

The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?

VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.

China is the third country to launch LEQEMBI for sale, to fight Alzheimer’s, following the United States and Japan.

Three FDA-Approved drugs, terazosin, doxazosin, and alfuzosin, have a happy side effect; they boost energy production in brain cells. New studies suggest this slows or prevents Dementia with Lewy Bodies.

The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.

South Korea joined other countries in approving LEQEMBI® (generic lecanemab) for mild cognitive impairment, mild and early Alzheimer’s. Learn how Leqembi is treating Alzheimer’s around the world.

CBS VIDEO – MUSIC & SONG: One program is giving people living with Alzheimer’s a new and joyous way to step back into life, by literally giving voice to both patients and their caregivers. Dr. Jonathan LaPook reports.

DIAGNOSIS VIDEO: Recognize the 10 early signs of dementia. Watch this engaging, clear presentation by Dementia Care Trainer Teepa Snow.

DIET VIDEO: What is the link between weight loss, mental performance, decision-making and dementia risk?

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.